Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vicotrat is a brand of pharmaceutical-grade vitamin supplements developed and marketed by Heyl Berlin, primarily used for the treatment and prevention of specific vitamin deficiencies. The product line includes Vicotrat B12, which contains hydroxocobalamin (a natural form of Vitamin B12), and Vicotrat B1, which contains thiamine. Hydroxocobalamin serves as an essential cofactor for enzymes such as methionine synthase and methylmalonyl-CoA mutase, which are critical for DNA synthesis, hematopoiesis, and the maintenance of the nervous system. Thiamine, in its active form thiamine pyrophosphate, is a vital cofactor for enzymes in carbohydrate metabolism and energy production, including pyruvate dehydrogenase and transketolase. Vicotrat is indicated for clinically significant deficiency states that cannot be managed through diet alone, such as pernicious anemia, malabsorption syndromes, or metabolic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vicotrat.